健康者和急性白血病患者体内苯唑西林对阿米卡星药代动力学的影响

 目的:对阿米卡星(AMK)与苯唑西林(OXA)合用健康者和急性白血病患者体内药代动力学进行研究。方法:微量微生物法测定AMK血、尿药浓度。结果:单用与合用AMK的药时曲线均符合二房室模型,健康者体内AMK单用与合用药代动力学参数分别为:K₁₀(0.55±0.22)和(0.42±0.03)h^-1(P<0.05),t_{1/2β(2.11±0.16)和(3.00±0.41)h(P<0.01);AUC(54.7±3.90)和(69.15±4.91)μg·h·ml^-1(P<0.001);急性白血病患者体内,AMK单用与合用药代动力学参数分别为:K12(0.06±0.26)和(1.06±0.10)h^-1(P<0.05),K21(1.47±0.64)和(1.84±0.22)h^-1(P<0.05)。K10(0.71±0.05)和(0.54±0.04)h^-1(P<0.05),t1/2β(1.62±0.19)和(2.22±0.09)h(P<0.01),AUC(39.92±4.20)和(51.53±3.00)μg·h·ml^-1(P<0.001)。结论:健康者和急性白血病患者体内OXA对AMK的药代动力学均有显著的影响。}

Influence of oxacillin on pharmacokinetics of amikacin in healthy volunteers and patients with acute leukaemia

OBJECTIVE:To study the pharmacokinetics of amikacin (AMK) combined with oxacillin (OXA) in healthy volunteers and patients with acuter leukaemia.METHOD:The AMK concentrations in serum and urine were detected by an improved microbiologial method.RESULTS:The serum drug concentration-time curve of AMK in healthy volunteers and patients with acute leukaemia were adequately fitted to two-compartment open model.AMK alone and combined group in healthy volunteers,K₁₀ (0.55±0.02) and (0.42±0.03)h^-1(P<0.05),t_1/2β(2.11±0.16) and (3.00±0.41)h (P<0.01),AUC(54.77±3.90)and(69.15±4.91)μg·h·ml^-1(P<0.001);AMK alone and combined group in patients with acute leukaemia,K₁₂(0.06±0.26)and(1.06±0.10)h^-1(P<0.05),K₂₁(1.47±0.64)and(1.84±0.22)h^-1(P<0.05),K₁₀(0.71±0.05) and (0.54±0.04)h^-1(P<0.05),t_1/2β(1.62±0.19) and (2.22±0.09)h (P<0.01),AUC(39.92±4.20) and (51.53±3.00)μg·h·ml^-1 (P<0.001).CONCLUSION:OXA had apparently influence on the pharmacokinetics of AMK in healthy volunteers and patients with acute leukaemia.